bioRxiv: Research and development of neutralizing therapeutic antibodies that can neutralise both SARS-CoV-2 and SARS-CoV!

, June 17, 2020 /PRNewswire/
-- The COVID-19 pandemic caused by the SARS-CoV-2 virus has created an unprecedented public health crisisThere are currently no approved vaccines or treatments for COVID-19recently, researchers from the Institute of Biophysics of the Chinese Academy of Sciences, the Academy of Military Medicine, the National Institute of Food and Drug Control and other institutions reported on a humanized monoclonal antibody H014, which effectively neutralizes SARS-CoV-2 and SARS-CoV pseudo-viruses and the real SARS-CoV-2 atnano-
levels by binding to the S receptor region (RBD)The study is now published on the preprinted platform bioRxiv and is entitled "Structure basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody"Photo Source: BioRxiv
Important, researchers found that H014 reduced the replication of SARS-CoV-2 in hACE2 mouse models and prevented lung pathologyresearchers revealed a new conformation epitope by using cryogenic electroscopy of the SARS-CoV-2 S triple polymer in conjunction with the H014 Fab fragment, which can only be obtained when the RBD is in open conformationbiochemical, cellular, virological and structural studies have shown that H014 prevents SARS-CoV-2 from adhering to host cell receptorsA wide range of cross-protected tabs were found in the profiling of available anti-SARS-CoV and SARS-CoV-2 neutralizing antibodiesoverall, the findings highlight the key role of antibody-based therapeutic interventions in COVID-19 therapy(BioValleyBioon.com)References:Zhe Lv et al.
Structure basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody bioRxiv 2020 doi: https://doi.org/10.1101/2020.06.02.129098